Becton, Dickinson and Company $BDX Shares Sold by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 117,941 shares of the medical instruments supplier’s stock after selling 24,239 shares during the period. Caisse de depot et placement du Quebec’s holdings in Becton, Dickinson and Company were worth $17,848,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $25,000. SHP Wealth Management acquired a new position in Becton, Dickinson and Company during the fourth quarter worth about $26,000. Meeder Asset Management Inc. grew its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the period. Main Street Group LTD purchased a new position in Becton, Dickinson and Company in the first quarter valued at about $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at approximately $29,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 0.8%

Shares of NYSE:BDX opened at $189.71 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $52.27 billion, a P/E ratio of 57.14, a P/E/G ratio of 13.26 and a beta of 0.19. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07. The stock’s fifty day simple moving average is $166.14 and its 200-day simple moving average is $160.53.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Analysts Set New Price Targets

Several brokerages have recently commented on BDX. TD Cowen boosted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $185.67.

Insider Activity

In other news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,869 shares of company stock worth $1,994,719 in the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.